Table 2.

Prospective cardiovascular safety trials for SGLT2 inhibitors(9)

Name of Trial	Intervention	Primary Endpoint	No. of Patients	Duration of Trial (y)	Projected Year of Completion
Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME)	Empagliflozin 10 or 25 mg daily	Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal MI), nonfatal MI, and nonfatal stroke	7000	5	2015
Canagliflozin cardiovascular Assessment Study (CANVAS)	Canagliflozin 100 or 300 mg daily	Major adverse cardiovascular events, including CV death, nonfatal MI, and nonfatal stroke	4330	≥ 4	2017
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)	Canagliflozin 100 mg daily	Time to the first occurrence of an event in the primary composite endpoint: ESRD, doubling of serum creatinine, renal or CV death	3627	5.5	2019
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)	Dapagliflozin 10 mg daily	Time to first event included in the composite end point of CV death, MI or ischemic stroke	17150	6	2019
Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (NCT01986881)	Ertugliflozin 5 or 15 mg daily	Time to first occurrence of any component of the composite endpoint of CV death, nonfatal MI, or nonfatal stroke	3900	6.3	2020